-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$8.83-34.98% Downside
Bioventus Inc. Frequently Asked Questions
-
What analysts cover Bioventus Inc.?
Bioventus Inc. has been rated by research analysts at Canaccord Genuity, Craig-Hallum, Goldman Sachs in the past 90 days.